NeuroPoint Gesellschaft fur vorbeugende Gesundheitspflege GmbH
- Address
- lock Available on a paid plan
Musculoskeletal Diseases
At NeuroPoint Gesellschaft fur vorbeugende Gesundheitspflege GmbH, research in the musculoskeletal domain focuses on chronic pain conditions such as migraine and diabetic peripheral neuropathic pain, aiming to test preventive and symptomatic therapies.
- Evaluation of preventive treatments for chronic migraine
- Assessment of medical cannabis inhalation for diabetic peripheral neuropathic pain
- Long‑term safety monitoring of novel analgesic agents
- Patient‑centered outcomes to gauge impact on daily functioning
These studies contribute to improving long‑term management options for patients with pain‑related disorders.
Nervous System Diseases
The centre’s work on multiple sclerosis spans relapsing and progressive forms, evaluating the safety and efficacy of disease‑modifying agents like ocrelizumab and novel oral compounds.
- Long‑term safety of disease‑modifying therapies in relapsing multiple sclerosis
- Comparative effectiveness of new oral agents versus established treatments
- MRI‑based monitoring of inflammatory activity and lesion development
- Strategies to delay disability progression in progressive multiple sclerosis
Through these trials, the site seeks to enhance disease control and reduce disability progression for individuals living with neurological disease.
Mental Disorders
In the mental health arena, investigators address depression by assessing new therapeutic options such as phytopharmaceuticals, with the goal of alleviating symptoms and improving patient‑reported outcomes.
- Testing novel phytopharmaceuticals for mild to moderate major depressive disorder
- Evaluation of symptom change using standardized depression rating scales
- Analysis of responder and remission rates to determine clinical relevance
- Safety and tolerability profiling of emerging antidepressant candidates
The ongoing work supports evidence‑based advances in treating mild to moderate major depressive disorder.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 72 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 69 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1F. Hoffmann-La Roche AG3active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG5trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NeuroPoint Gesellschaft fur vorbeugende Gesundheitspflege GmbH
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 72 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 6 | Unknown | 2018-05-02 | 2026-02-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.